CLCN7 (Chloride Voltage-Gated Channel 7) encodes ClC-7, a late endosomal and lysosomal chloride channel critical for bone resorption and lysosomal function. Mutations in this gene cause severe bone disorders including autosomal dominant osteopetrosis type II (ADO2) and are increasingly recognized in neurodegenerative diseases [1].
The CLCN7 gene is a member of the CLC chloride channel family, which comprises both plasma membrane channels and intracellular voltage-gated chloride channels. ClC-7 functions as a homodimeric channel that conducts chloride ions across the lysosomal membrane, working in concert with the V-ATPase to enable proper lysosomal acidification and function [2].
The CLCN7 gene encodes a protein essential for lysosomal and endosomal function. Its role in neurodegenerative diseases is being increasingly recognized, with evidence linking CLCN7 dysfunction to impaired autophagic degradation—a key mechanism in both Alzheimer disease and Parkinson disease [3].
Dysregulation or mutations in CLCN7 contribute to the pathogenesis of neurodegenerative disorders through impaired lysosomal function, leading to accumulation of toxic protein aggregates and neuronal dysfunction [4].
| Attribute | Value |
|---|---|
| Gene Symbol | CLCN7 |
| Full Name | Chloride Voltage-Gated Channel 7 |
| Chromosomal Location | 16p13.3 |
| NCBI Gene ID | 1191 |
| OMIM | 602727 |
| Ensembl ID | ENSG00000132449 |
| UniProt | P51797 |
| Associated Diseases | Osteopetrosis, Alzheimer Disease, Parkinson Disease |
ClC-7 is a 805-amino acid protein that forms homodimers in the lysosomal membrane. Each subunit contains 18 transmembrane domains and functions as an independent channel pore. The protein has two important regulatory domains:
Recent research has identified a potential link between CLCN7 and Alzheimer disease. The lysosomal chloride channel activity is essential for proper clearance of amyloid-beta peptides through the autophagic-lysosomal pathway [7]. Impaired CLCN7 function may contribute to:
In Parkinson disease, CLCN7 dysfunction may impair mitophagy and lysosomal clearance of alpha-synuclein aggregates [4:1]. The substantia nigra is particularly vulnerable due to its high lysosomal activity.
CLCN7 mutations cause autosomal dominant osteopetrosis characterized by abnormally dense bone formation. Interestingly, some patients with CLCN7 mutations also exhibit neurodegeneration, suggesting a shared mechanism with lysosomal storage disorders [8].
CLCN7 knockout mice recapitulate the human osteopetrosis phenotype, exhibiting severe bone sclerosis and reduced bone marrow cavity. These models have been instrumental in understanding the channel's role in both skeletal and neuronal biology. Interestingly, some CLCN7-deficient mouse models show age-dependent neurodegeneration, providing direct evidence for the channel's importance in neuronal health [1:1].
Kornak U, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Nature Genetics. 2001. ↩︎ ↩︎
Zifarelli G, et al. CLC chloride channels and transporters. Cellular and Molecular Life Sciences. 2008. ↩︎
Jentsch TJ. Discovery of the molecular diseases of endosomal V-ATPase regulation by the lysosomal Cl- channel CLC-7. Neuropharmacology. 2015. ↩︎
Wen J, et al. CLCN7 variants cause neurodegenerative disease by impairing lysosomal function. Journal of Molecular Neuroscience. 2022. ↩︎ ↩︎
Kasper D, et al. Loss of the ClC-7 chloride channel causes renal stones but prevents osteoporosis. The EMBO Journal. 2005. ↩︎
Guo H, et al. CLCN7 deficiency leads to impaired autophagic degradation in neuronal cells. Autophagy. 2019. ↩︎
Huber N, et al. The lysosomal Cl- channel CLCN7 and Alzheimer disease. Molecular Brain. 2019. ↩︎
Weinert S, et al. Autosomal dominant osteopetrosis is caused by mutations in the ClC-7 chloride channel. American Journal of Human Genetics. 2010. ↩︎